Physician profile
Ramzi E Abdulrahman
NPI 1790718203
$2,958.22
in general payments reported to CMS, 2019-2025
31 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $37.92 · 2021: $119 · 2022: $503 · 2023: $895 · 2024: $217 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $492.46 | 2019-2025 | Imfinzi |
| Siemens Medical Solutions USA, INC. | $358.31 | 2022-2025 | Truebeam, Varian Ethos Treatment Planning, Biograph Vision 600 (8 Ring/64 Ct) |
| Novocure INC. | $267.27 | 2021-2023 | Optune |
| Reflexion Medical, INC. | $241.86 | 2023 | Reflexion Medical Radiotherapy System |
| Seagen INC. | $194.83 | 2023 | Adcetris, Padcev |
| Boston Scientific Corporation | $166.51 | 2019-2025 | Spaceoar Vue System - 10ml |
| Medtronic USA, INC. | $160.63 | 2019 | |
| Roche Diagnostics Corporation | $154.58 | 2022 | |
| Amgen INC. | $154.42 | 2019 | |
| Elekta, INC. | $109.81 | 2023-2024 | Elekta Medical Linear Accelerator |
| Genzyme Corporation | $91.69 | 2019-2025 | |
| Viewray Technologies INC | $64.92 | 2022 | |
| Varian Medical Systems, INC. | $63.96 | 2019 | |
| Dendreon Pharmaceuticals LLC | $57.15 | 2024 | Provenge |
| Tersera Therapeutics LLC | $52.28 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zap Surgical Systems, INC. | $35.11 | 2022 | |
| Myriad Genetic Laboratories, INC. | $33.12 | 2022 | |
| Incyte Corporation | $31.64 | 2019 | |
| Ge Healthcare | $24.85 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.62 | 2019 | |
| Abbvie INC. | $21.26 | 2025 | |
| Visionrt, INC. | $21.13 | 2019 | |
| Eisai INC. | $17.27 | 2019 | |
| Celgene Corporation | $16.67 | 2020 | |
| Advanced Accelerator Applications | $16.40 | 2019 | |
| Cardinal Health 414 LLC | $13.74 | 2019 | |
| Tactile Systems Technology INC | $13.44 | 2023 | Flexitouch Plus, Entre Plus |
| Janssen Pharmaceuticals, INC | $12.93 | 2019 | |
| Exelixis INC. | $11.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramzi Abdulrahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.